OpGen > Company > OpGen Team

OpGen Team

Evan Jones, Chairman and CEO

Evan Jones Mr. Jones is the Managing Member of jVen Capital, LLC, a life sciences investment company. Prior to forming jVen Capital, he was co-founder, Chairman and CEO of Digene  Corporation, a publicly traded biotechnology company focused on women’s health and molecular diagnostic testing. He is a Board Member of Fluidigm, Inc., Foundation  Medicine, Inc., and Veracyte, Inc. Mr. Jones is Vice-Chairman of the Board of the Children’s National Medical Center and a Board Member of the Children’s Research Institute.  Mr. Jones is Chairman of the Board for the Campaign for Public Health, an organization dedicated to making public health and prevention a higher national priority. He serves on the Board of Directors of Research!America.

Mr. Jones received his BA degree from the University of Colorado and an MBA from The Wharton School, University of Pennsylvania.

Eric Winzer, CFO

Eric Winzer, Chief Financial OfficerMr. Winzer joined OpGen as Chief Financial Officer in June 2009. Eric brings almost 30 years of experience in addressing diverse financial issues including raising capital, financial reporting, investor relations, banking, taxation, mergers and acquisitions, financial planning and analysis, and accounting operations. Eric is responsible for all financial functions at the Company.

Prior to joining Opgen, Eric served as Executive Vice President and Chief Financial Officer for Avalon Pharmaceuticals, Inc., a biotechnology company developing targeted therapeutics for oncology. Prior to Avalon, Eric was with Life Technologies Corporation (formerly Invitrogen Corporation), a provider of life science technologies for disease research and drug discovery, where he served as Senior VP and Chief Financial Officer, Executive Sponsor for Life’s ERP implementation, and as the VP of Finance. Previously held positions also include Eric’s tenure at Life Technologies Incorporated, where he assumed increasing responsibility as Chief Financial Officer, Secretary and Treasurer, and additionally held various financial positions at Genex Corporation. Currently, Eric serves as director and audit committee chair at Cytomedix, Inc.

Eric received his BA in Economics and Business Administration from McDaniel College and an MBA from Mount Saint Mary’s University.

Tom Ross, Sr. VP, Commercial Operations

 Mr. Ross has extensive experience in all elements of commercial operations and has over 25 years of successful sales and marketing leadership in the Life Science and Clinical  Diagnostics markets. Most recently Tom served as Chief Commercial Officer at Predictive BioSciences, a molecular diagnostics laboratory with a focus on Bladder and Prostate  cancer. Prior to Predictive BioSciences, he was the Vice President of North America Medical Diagnostics Sales at QIAGEN/Digene Corporation. Prior to Digene, Tom held  several senior leadership roles at Life Technologies and Cambrex. In addition to his sales and marketing experience, Tom held management positions in Manufacturing  Operations at Life Technologies and Cambrex.

Tom holds a BS in Business Administration from The Citadel.

Vadim Sapiro, CIO

Vadim Sapiro, CIOMr. Sapiro joined OpGen in December, 2011 with responsibility for leading the development of the Company’s bioinformatics applications, software, databases and information technology operations. Prior to OpGen, Vadim was senior vice president at SAIC-Frederick overseeing the Information Systems Program for the National Cancer Institute at Frederick with responsibility for information technology, scientific computing and bioinformatics. Among Vadim’s projects were technical program management and operations for the cancer Biomedical Informatics Grid (caBIG™), the cancer Human Biobank (caHUB) and The Cancer Genome Atlas (TCGA). Prior to SAIC, Vadim was vice president for information technology with the J. Craig Venter Institute.  Vadim is active in the regional and national technology and research communities, having served on many life sciences and biotech focused advisory boards and review committees.

Vadim holds a BS in Mathematics and Computer Science from the University of Maryland.

Terry Walker, VP, Research & Development

Dr. Walker’s  responsibilities include leading the development of genomic technologies and new products supporting molecular diagnostics for infectious diseases.  Prior to OpGen, Terry previously  led drug target validation , biomarker discovery and clinical diagnostic development at Pfizer, GlaxoSmithKline (GSK), Becton Dickinson (BD), Duke University and The Biomarker Factory across most disease areas and stages of development from discovery through late clinical trials.

 Terry received his PhD in Biophysical Chemistry from the University of Rochester with postdoctoral training in Biophysical Chemistry at the University of California, Berkeley.

 

David Hoekzema, VP, Business Development & Operations

Mr. Hoekzema joined OpGen in 2012 to expand technology and assay development partnerships in clinical diagnostics and life sciences.  David is also responsible for OpGen’s  production and service operations.  He has over 25 years of experience in global biotechnology markets, with leadership and management roles spanning business  development, sales and marketing, and commercial and technical operations at QIAGEN, Cambrex Biopharmaceuticals, Life Technologies, and Advanced Biotechnologies.  Prior  to OpGen, David was Vice President, Business Development at SAIC, leading the formation of technology partnerships for Frederick National Laboratory for Cancer Research.

David holds a BS in Biology from Frostburg State University and an MBA from the University of Maryland, Robert H. Smith School of Business.

“Physical map and genetic map still should be emphasized as an important parts of a reference genome. Recent progress in technologies, such as the whole genome mapping high-throughput platform offered by OpGen, now provide the tools for efficient physical map construction. This independent technology provides not only the validation of the genome sequencing, but also provides the large-scale chromosome structure information that cannot be detected by sequencing. We applied this technology as an assistant tool of the NGS to assemble bacterial, plant and large mammalian genome with reliable accuracy and generate the sub-chromosome graded assembly. The experience in these genome assembly projects shows that the physical map should be the standard for any reference genome to be assembled in further.”

Xun Xu, Ph.D.

Deputy Director at BGI
 

This independent technology provides not only the validation of the genome sequencing, but also provides the large-scale chromosome structure information that cannot be detected by sequencing.

Xun Xu, Ph.D.
Deputy Director at BGI

“Our research focuses on a wide variety of projects from viruses and microbes to crop plants and mammals. Many of our projects are de novo assembly projects, where, without a closely related genome sequence, it can be difficult to critically assess the results. We often combine different sequencing technologies, and we are finding that regardless of the sequencing platform, error correction, or assembler used, OpGen’s Whole Genome Mapping identifies misassemblies and provides the highest quality de novo assembly for further research.”

Matthew Clark, Ph.D.

Team Leader, Sequencing Technology Development

The Genome Analysis Centre (TGAC), Norwich, UK

OpGen’s Whole Genome Mapping identifies misassemblies and provides the highest quality de novo assembly for further research.

Matthew Clark, Ph.D.
Team Leader, Sequencing Technology Development

“We adopted OpGen’s Argus System as the most advanced way of adding Whole Genome Mapping to improve whole genome sequences. We combined Whole Genome Maps with sequence assemblies to correct errors and misassemblies in bacterial genome sequences as part of our program in the Human Microbiome Project. We are now moving the technology into larger genome projects.”


George Weinstock, Ph.D.

Associate Director
 The Genome Institute at Washington University

We combined Whole Genome Maps with sequence assemblies to correct errors and misassemblies in bacterial genome sequences. This is part of our program from the Human Microbiome Project.

George Weinstock Ph.D.

Associate Director

The Genome Institute at Washington University

“Certain things you just have a tough time answering with de novo sequencing. And assembly doesn’t always work out as sweetly as you would like. So definitely for any whole genome de novo project that people are insistent on closing we would do a Whole Genome Map optically as well as de novo assembly. And the amount of money you would save is in the thousands of dollars in finishing.”

Stefan Green

Director of DNA Services

University of Illinois Chicago Research Resources Center (UIC RRC)

Definitely for any whole genome de novo project that people are insistent on closing we would do a Whole Genome Map.

Stefan Green
Director of DNA Services

“Physical map and genetic map still should be emphasized as an important parts of a reference genome. Recent progress in technologies, such as the whole genome mapping high-throughput platform offered by OpGen, now provide the tools for efficient physical map construction. This independent technology provides not only the validation of the genome sequencing, but also provides the large-scale chromosome structure information that cannot be detected by sequencing. We applied this technology as an assistant tool of the NGS to assemble bacterial, plant and large mammalian genome with reliable accuracy and generate the sub-chromosome graded assembly. The experience in these genome assembly projects shows that the physical map should be the standard for any reference genome to be assembled in further.”

Xun Xu, Ph.D.

Deputy Director at BGI
 

This independent technology provides not only the validation of the genome sequencing, but also provides the large-scale chromosome structure information that cannot be detected by sequencing.

Xun Xu, Ph.D.
Deputy Director at BGI

“Our research focuses on a wide variety of projects from viruses and microbes to crop plants and mammals. Many of our projects are de novo assembly projects, where, without a closely related genome sequence, it can be difficult to critically assess the results. We often combine different sequencing technologies, and we are finding that regardless of the sequencing platform, error correction, or assembler used, OpGen’s Whole Genome Mapping identifies misassemblies and provides the highest quality de novo assembly for further research.”

Matthew Clark, Ph.D.

Team Leader, Sequencing Technology Development

The Genome Analysis Centre (TGAC), Norwich, UK

OpGen’s Whole Genome Mapping identifies misassemblies and provides the highest quality de novo assembly for further research.

Matthew Clark, Ph.D.
Team Leader, Sequencing Technology Development

“We adopted OpGen’s Argus System as the most advanced way of adding Whole Genome Mapping to improve whole genome sequences. We combined Whole Genome Maps with sequence assemblies to correct errors and misassemblies in bacterial genome sequences as part of our program in the Human Microbiome Project. We are now moving the technology into larger genome projects.”


George Weinstock, Ph.D.

Associate Director
 The Genome Institute at Washington University

We combined Whole Genome Maps with sequence assemblies to correct errors and misassemblies in bacterial genome sequences. This is part of our program from the Human Microbiome Project.

George Weinstock Ph.D.

Associate Director

The Genome Institute at Washington University

“Certain things you just have a tough time answering with de novo sequencing. And assembly doesn’t always work out as sweetly as you would like. So definitely for any whole genome de novo project that people are insistent on closing we would do a Whole Genome Map optically as well as de novo assembly. And the amount of money you would save is in the thousands of dollars in finishing.”

Stefan Green

Director of DNA Services

University of Illinois Chicago Research Resources Center (UIC RRC)

Definitely for any whole genome de novo project that people are insistent on closing we would do a Whole Genome Map.

Stefan Green
Director of DNA Services

CLOSE